What are the FDA 361 HCT/P criteria and what do they mean for clinics?

By XLR8 Medical Editorial Team ยท Updated

Short answer

Under 21 CFR 1271.10(a), an HCT/P is regulated solely under section 361 of the Public Health Service Act only if it meets all four criteria: minimal manipulation, homologous use only, no combination with another article beyond narrow exceptions, and a condition on systemic effect and metabolic activity. An HCT/P that misses any one, and qualifies for no exception in 21 CFR 1271.15, is regulated as a drug, device or biological product. For a clinic, that means getting each product's documented basis from its supplier.

What an HCT/P is

21 CFR 1271.3(d) defines human cells, tissues, or cellular or tissue based products (HCT/Ps) as articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient. The same paragraph lists articles that are not HCT/Ps, including vascularized human organs for transplantation, whole blood and blood components, and secreted or extracted human products.

The rules for HCT/Ps sit in 21 CFR Part 1271. Under 21 CFR 1271.1, their stated purpose includes registration and listing of establishments that manufacture HCT/Ps, and procedures to keep HCT/Ps from introducing, transmitting or spreading communicable diseases. In this part, "manufacture" is broad: 21 CFR 1271.3(e) includes recovery, processing, storage, labeling, packaging and distribution.

The four criteria in 21 CFR 1271.10(a)

21 CFR 1271.10(a) sets the test. Its opening words:

"An HCT/P is regulated solely under section 361 of the PHS Act and the regulations in this part if it meets all of the following criteria" 21 CFR 1271.10(a)

All four must be met. In the regulation's order:

1. Minimally manipulated

The HCT/P is minimally manipulated. The term is defined in 21 CFR 1271.3(f), with one definition for structural tissue and another for cells or nonstructural tissues.

2. Intended for homologous use only

The HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent. Homologous use is defined in 21 CFR 1271.3(c). Because this criterion is judged from labeling, advertising and other statements, how a product is described is part of the test.

3. Not combined with another article

The manufacture of the HCT/P does not involve combining the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, and only if adding them does not raise new clinical safety concerns with respect to the HCT/P.

4. Systemic effect and metabolic activity

Either the HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function, or, if it does have a systemic effect or depend on that activity, it is for autologous use, for allogeneic use in a first-degree or second-degree blood relative, or for reproductive use.

An establishment that manufactures an HCT/P meeting these criteria must register with FDA, list each HCT/P it manufactures, and comply with the rest of Part 1271 (21 CFR 1271.10(b)).

How FDA reads "minimally manipulated" and "homologous use"

FDA explains these two criteria in its guidance Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use (July 2020). Guidance is FDA's current thinking and is not binding on FDA or the public; the regulation is what binds.

On minimal manipulation, the guidance says:

  • An HCT/P is considered either structural tissue or cells and nonstructural tissue, decided by its characteristics in the donor, before recovery and before any processing.
  • Tissues that physically support or serve as a barrier or conduit, or connect, cover, or cushion are generally structural. Those with metabolic or other biochemical roles are generally cells or nonstructural tissues.
  • Whether an HCT/P is minimally manipulated depends on the effect of manufacturing on its original relevant characteristics as it existed in the donor, not on its intended use in the recipient.
  • All of the processing steps should be considered.

On homologous use, the guidance says FDA first determines the intended use from the labeling, advertising and other indications of the manufacturer's objective intent, and then applies the definition. It counts internet advertising and statements of company representatives as advertising. It also says:

"If an HCT/P is intended for use as an unproven treatment for a myriad of diseases or conditions, the HCT/P is likely not intended for homologous use only." FDA guidance, July 2020

The guidance works through examples for particular tissues. This guide does not restate them, because the outcome in each example depends on the specific product and its labeled use. Read the guidance itself.

What "361" does not mean

Meeting the criteria does not mean FDA has reviewed or cleared the product. FDA's guidance describes the 361 tier as covering HCT/Ps that do not require premarket review. Registration is not a finding either:

"FDA acceptance of an establishment registration and HCT/P listing form does not constitute a determination that an establishment is in compliance with applicable rules and regulations or that the HCT/P is licensed or approved by FDA." 21 CFR 1271.27(b)

FDA's HCTERS public query page adds that registration and listing is not a determination that an HCT/P is appropriately regulated solely under section 361. FDA's consumer page on regenerative medicine therapies warns of broad marketing of unapproved products and says that a firm having registered with FDA and listed its product does not mean the product is legally marketed.

What it means day to day for a clinic

The criteria are written for manufacturers, but a clinic that buys and uses HCT/Ps still needs to know the basis for each product's status. Before using a product, ask the supplier for:

  • The manufacturing establishment's FDA registration, and check it yourself in FDA's HCTERS public query, remembering that registration is not a determination of status.
  • The manufacturer's written basis for saying the product meets each of the four criteria for its labeled use.
  • Whether the manufacturer has asked FDA's Tissue Reference Group for a recommendation or filed a Request for Designation for a formal decision. FDA's guidance describes both routes.
  • The product's labeling and the uses it states, because homologous use is judged from labeling, advertising and other statements. Keep your clinic's own wording consistent with them; see how to market regenerative services compliantly.

Part 1271 also has exceptions. 21 CFR 1271.15(d) excepts an establishment that does not recover, screen, test, process, label, package, or distribute, but only receives or stores HCT/Ps solely for implantation, transplantation, infusion, or transfer within its own facility. Whether a clinic's activities fit that description is a question for its healthcare attorney.

When the criteria are not met

21 CFR 1271.20 says that an HCT/P that does not meet the 1271.10(a) criteria, made by an establishment that qualifies for no exception in 1271.15, is regulated as a drug, device, and/or biological product under the Federal Food, Drug, and Cosmetic Act and/or section 351 of the Public Health Service Act. FDA's guidance says premarket review will be required for such HCT/Ps, and section 351 itself, at 42 U.S.C. 262(a), bars introducing a biological product into interstate commerce unless a biologics license is in effect.

For certain HCT/Ps, FDA had a period of enforcement discretion regarding the investigational new drug and premarket approval requirements, and it ended on May 31, 2021. FDA's questions and answers on the end of that policy say that a product that requires but lacks premarket approval may not be lawfully marketed. The difference between the two tiers is covered in 361 HCT/P vs 351 biologics.

Sources

Frequently asked questions

What does "361" refer to?

It refers to section 361 of the Public Health Service Act, which appears in the US Code at 42 U.S.C. 264 and authorizes regulations to stop the spread of communicable diseases. FDA's rules for human cells, tissues and cellular and tissue based products in 21 CFR Part 1271 rest on that authority. An HCT/P that meets all of the criteria in 21 CFR 1271.10(a) is regulated solely under section 361 and Part 1271.

What does "minimally manipulated" mean?

21 CFR 1271.3(f) gives two definitions. For structural tissue, it means processing that does not alter the original relevant characteristics of the tissue relating to the tissue's utility for reconstruction, repair, or replacement. For cells or nonstructural tissues, it means processing that does not alter their relevant biological characteristics. FDA's guidance says the test looks at the effect of all the processing steps on the HCT/P as it exists in the donor, not at its intended use in the recipient.

What does "homologous use" mean?

21 CFR 1271.3(c) defines homologous use in terms of an HCT/P performing the same basic function or functions in the recipient as in the donor. Under 21 CFR 1271.10(a)(2), an HCT/P must be intended for homologous use only, as reflected by its labeling, advertising or other indications of the manufacturer's objective intent. FDA's guidance says it decides the intended use from those materials first and then applies the definition.

Does FDA approve 361 HCT/Ps?

No. FDA's guidance explains that HCT/Ps meeting all of the criteria in 21 CFR 1271.10(a) do not require premarket review and approval. Meeting the criteria in 21 CFR 1271.10(a) does not mean FDA has approved a product. Under 21 CFR 1271.27(b), FDA's acceptance of an establishment registration and HCT/P listing is not a determination that the establishment complies with the rules or that the HCT/P is licensed or approved.

Who is responsible for deciding that a product meets the criteria?

21 CFR 1271.10 is written for the establishment that manufactures the HCT/P. FDA's guidance describes two ways a manufacturer can get FDA's view: an informal recommendation from the Tissue Reference Group, or a formal decision through a Request for Designation. A clinic that uses a product should get the manufacturer's basis in writing and review it with a healthcare attorney.

What is the same surgical procedure exception?

21 CFR 1271.15(b) excepts an establishment that removes HCT/Ps from an individual and implants them into the same individual during the same surgical procedure. FDA's guidance on the exception calls it narrow: the cells or tissues must be autologous, implanted within the same surgical procedure, and kept in their original form, which generally allows only rinsing, cleansing, sizing and shaping.